CSF3 and neutropenia: Patients with ANC above 500/mm3 but recent myelosuppressive treatment, significant clinical signs of immune compromise, or recent G-CSF use often demonstrated clinical trajectories similar to those of patients with severe neutropenia, supporting their inclusion in the febrile neutropenia group.